Phenylketonuria: A 21 st century perspective

Nature Reviews Endocrinology

Volumn 6, Issue 9, 2010, Pages 509-514

  Van Spronsen, Francjan J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLYCOPROTEIN; LARGE NEUTRAL AMINO ACID; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; PHENYLALANINE AMMONIA LYASE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; BEHAVIOR DISORDER; DIET RESTRICTION; EPILEPSY; GENE THERAPY; HUMAN; MENTAL DEFICIENCY; MISSENSE MUTATION; NEWBORN SCREENING; NONHUMAN; OUTCOME ASSESSMENT; PHENYLKETONURIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN RESTRICTION; REVIEW; SOCIAL PSYCHOLOGY; BIOLOGICAL MODEL; DIET THERAPY; ENDOCRINOLOGY; HISTORY; METHODOLOGY; NEWBORN; TREATMENT OUTCOME;

DIET THERAPY; ENDOCRINOLOGY; HISTORY, 21ST CENTURY; HUMANS; INFANT, NEWBORN; MODELS, BIOLOGICAL; NEONATAL SCREENING; PHENYLKETONURIAS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 77955887072     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.125     Document Type: Review

References (51)

1. Zschocke, J. Phenylketonuria mutations in europe. Hum. Mutat. 21, 345-356 (2003).
2. Følling i. The discovery of phenylketonuria. Acta Paediatr. 83 (Suppl. 407), S4-S10 (1994).
3. Bickel, H., Gerrard, J. & Hickmans, e. M. influence of phenylalanine intake on phenylketonuria. Lancet 265, 812-813 (1953).
4. Guthrie, R. & Susi, A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32, 338-343 (1963).
5. Loeber, J. G. Neonatal screening in europe; the situation in 2004. J. Inherit. Metab. Dis. 30, 430-438 (2007).
6. Zurflüh, M. R. et al. Screening for tetrahydrobiopterin deficiencies using dried blood spots on filter paper. Mol. Genet. Metab. 86 (Suppl. 1), S96-S103 (2005).
7. van Spronsen, F. J. & enns, G. M. Future treatment strategies in phenylketonuria. Mol. Gen. Metab. 99 (Suppl. 1), S90-S95 (2010).
8. Smith, i., Beasley, M. G. & Ades, A. e. intelligence and quality of dietary treatment in phenylketonuria. Arch. Dis. Child. 65, 472-478 (1990).
9. verkerk, P. H., vaandrager, G. J. & Sengers R. C. 15 years of national screening for phenylketonuria in The Netherlands; 4th Report of the National Commission for Management of Phenylketonuria [in Dutch]. Ned Tijdschr Geneeskd. 134, 2533-2536 (1990).
10. Gassió, R. et al. School performance in early and continuously treated phenylketonuria. Pediatr. Neurol. 33, 267-271 (2005).
11. Huijbregts, S. C. et al. Motor function under lower and higher controlled processing demands in early and continuously treated phenylketonuria. Neuropsychology 17, 369-379 (2003).
12. Christ, S. e, Huijbregts, S. C., de Sonneville, L. M. & white, D. A. executive function in early-treated phenylketonuria: Profile and underlying mechanisms. Mol. Gen. Metab. 99 (Suppl. 1), S22-S32 (2010).
13. Gentile J. K., Ten Hoedt, A. e. & Bosch, A. M. Psychosocial aspects of PKU: hidden disabilities. Mol. Gen. Metab. 99 (Suppl. 1), S64-S67 (2010).
14. van Spronsen, F. J. & Burgard, P. The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J. Inherit. Metab. Dis. 31, 673-679 (2008).
15. Albrecht, J., Garbade, S. F. & Burgard, P. Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci. Biobehav. Rev. 33, 414-421 (2009).
16. Koch, R. et al. Phenylketonuria in adulthood: A collaborative study. J. Inherit. Metab. Dis. 25, 333-346 (2002).
17. Pietz, J. et al. Psychiatric disorders in adult patients with early-treated phenylketonuria. Pediatrics 99, 345-350 (1997).
18. Lee, P. J., McKitterick, K., Channon, S. & Leach, A. improvements in neuropsychometric outcome when re-introducing diet in adulthood in phenylketonuria (PKU). J. Inherit. Metab. Dis. 30 (Suppl. 1), 14 (2007).
19. Koch, R., Trefz, F. & waisbren, S. Psychosocial issues and outcomes in maternal PKU. Mol. Gen. Metab. 99 (Suppl. 1), S68-S74 (2010).
20. Laclair, C. e., Ney, D. M., MacLeod, e. L. & etzel, M. R. Purification and use of glycomacropeptide for nutritional management of phenylketonuria. J. Food Sci. 74, e199-e206 (2009).
21. Ney, D. M. et al. Nutritional management of PKU with glycomacropeptide from cheese whey. J. Inherit. Metab. Dis. 32, 32-39 (2009).
22. Lim, K., van Calcar, S. C., Nelson, K. L., Gleason, S. T. & Ney, D. M. Acceptable low-phenylalanine foods and beverages can be made with glycomacropeptide from cheese whey for individuals with PKU. Mol. Genet. Metab. 92, 176-178 (2007).
23. van Calcar, S. C. et al. improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am. J. Clin. Nutr. 89, 1068-1077 (2009).
24. Andersen, A. e. & Avins, L. Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria. Arch. Neurol. 33, 684-686 (1976).
25. Pietz, J. et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J. Clin. Invest. 103, 1169-1178 (1999).
26. Moats, R. A., Moseley, K. D., Koch, R. & Nelson, M. Jr. Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults. Pediatrics 112, 1575-1579 (2003).
27. Schindeler, S. et al. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol. Genet. Metab. 91, 48-54 (2007).
28. Lou, H. Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria. Lancet 2, 150-151 (1985).
29. Matalon, R. et al. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J. Inherit. Metab. Dis. 30, 153-158 (2007).
30. Kaufman, S. & Milstien, S. Phenylketonuria and its variants. Ann. Clin. Lab. Sci. 7, 178-185 (1977).
31. Kure, S. et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J. Pediatr. 135, 375-378 (1999).
32. Burton, B. K. et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase ii, multicentre, open-label, screening study. J. Inherit. Metab. Dis. 30, 700-707 (2007).
33. Muntau, A. C. et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med. 347, 2122-2132 (2002).
34. Levy, H., Burton, B., Cederbaum, S. & Scriver, C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol. Genet. Metab. 92, 287-291 (2007).
35. Bernegger, C. & Blau, N. High frequency of tetrahydrobiopterin- responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002. Mol. Genet. Metab.77, 304-313 (2002).
36. Hennermann, J. B., Bührer, C., Blau, N., vetter, B. & Mönch, e. Long-term treatment with tetrahydrobiopterin increases phenylalanine tolerance in children with severe phenotype of phenylketonuria. Mol. Genet. Metab. 86 (Suppl. 1), S86-S90 (2005).
37. Dobrowolski, S. F. et al. A limited spectrum of phenylalanine hydroxylase mutations is observed in phenylketonuria patients in western Poland and implications for treatment with 6R tetrahydrobiopterin. J. Hum. Genet. 54, 335-339 (2009).
38. Pérez, B. et al. Kinetic and stability analysis of PKU mutations identified in BH4-responsive patients. Mol. Genet. Metab. 86 (Suppl. 1), S11-S16 (2005).
39. Gersting, S. w. et al. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am. J. Hum. Genet. 83, 5-17 (2008).
40. Blau, N. et al. Optimizing the use of sapropterin (BH4) in the management of phenylketonuria. Mol. Genet. Metab. 96, 158-163 (2009).
41. Sarkissian, C. N. et al. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc. Natl Acad. Sci. USA 96, 2339-2344 (1999).
42. Sarkissian, C. N. et al. Preclinical evaluation of multiple species of PeGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl Acad. Sci. USA 105, 20894-20899 (2008).
43. Kang, T. S. et al. Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria. Mol. Genet. Metab. 99, 4-9 (2010).
44. Harding, C. O. et al. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAv2/8 vector-mediated gene therapy in murine phenylketonuria. Gene Ther. 13, 457-462 (2006).
45. Ding, Z., Georgiev, P. & Thöny, B. Administrationroute and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adenoassociated virus 8 pseudotyped vector-mediated gene transfer. Gene Ther. 13, 587-593 (2006).
46. Ding, Z. et al. Correction of murine PKU following AAv-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol. Ther. 16, 673-681 (2008).
47. Rebuffat, A., Harding, C. O., Ding, Z. & Thöny, B. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Hum. Gene Ther. 21, 463-477 (2010).
48. Thöny, B. Long-term correction of murine phenylketonuria by viral gene transfer: liver versus muscle. J. Inherit. Metab. Dis. doi:10.1007/s10545- 010-9044-3.
49. Gregersen, N., Bross, P., vang, S. & Christensen, J. H. Protein misfolding and human disease. Annu. Rev. Genomics Hum. Genet. 7, 103-124 (2006).
50. Cohen, F. e. & Kelly, J. w. Therapeutic approaches to protein-misfolding diseases. Nature 426, 905-909 (2003).
51. Pey, A. L. et al. identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J. Clin. Invest. 118, 2858-2867 (2008).